<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04282434</url>
  </required_header>
  <id_info>
    <org_study_id>CLEOPAHTRA</org_study_id>
    <secondary_id>PRIN2017F8ZB89</secondary_id>
    <nct_id>NCT04282434</nct_id>
  </id_info>
  <brief_title>DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical Trial</brief_title>
  <acronym>CLEOPAHTRA</acronym>
  <official_title>CLinical Epigenetic-sensitive trajectOries Underlying Pulmonary Arterial Hypertension and neTwoRk Analysis (CLEOPAHTRA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify epigenetic-sensitive modifications and novel biomarkers linked to pathogenesis of
      pulmonary arterial hypertension (PAH), we will perform the first study analyzing
      differentially-methylated regions (DMRs) in circulating T cells (CD04+ and CD08+) isolated
      from peripheral blood of patients undergoing right heart catheterization. Moreover, we will
      perform RNA deep sequencing on lung tissue biopsies to validate if DNA methylation signatures
      in circulating T cells could reflect perturbations of gene expression in lung tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary arterial hypertension (PAH) is characterized by remodeling of pulmonary arteries
      caused by an inbalance of proliferation/apoptosis rate within the vascular wall. This
      pathological phenotype seems to be triggered by different environmental stress and injury
      events such as increased inflammation, DNA damage, and epigenetic deregulation. Many immune
      cells are increased in PAH, such as T and B lymphocytes. Remarkably, T cells are essential
      players of adaptive immunity and may be relevant initiators (&quot;initial hit&quot;) of vascular
      remodelling. We will perform the first multi-omics study to: 1) investigate DNA methylome of
      circulating T cells isolated from peripheral blood of PAH patients, 2) detect transcriptomic
      profiles of lung tissues, 3) to assess if DNA methylation of distinct genomic regions in
      circulating T cells could reflect modifications of lung gene expression programs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of differentially methylated regions in CD04 and CD08 T cells</measure>
    <time_frame>3 Months</time_frame>
    <description>Reduced Representation Bisulfite Sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of differentially expressed genes in lung tissue biopsies</measure>
    <time_frame>5 Months</time_frame>
    <description>Chip Microarray</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioinformatic analysis</measure>
    <time_frame>8 Months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Pulmonary Arterial Remodeling</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Circulating T cells Lung tissue biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        30 PAH patients (familial and idiopathic) vs 30 sex and age-matched subjects.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed patients with World Health Organization (WHO) Group I PAH.

          -  ≥ 18 years

          -  Documentation of the following hemodynamic parameters by right heart catheterization,
             performed at time of study enrolment:

          -  Mean pulmonary arterial pressure (mPAP) &gt; 25 mmHg at rest or mPAP &gt; 30 mm Hg with
             exercise.

          -  Pulmonary arterial wedge pressure (PAWP) ≤ 15 mm Hg.

          -  Pulmonary vascular resistance (PVR) ≥ 240 dynes.sec.cm-5 (e.g., ≥ 3.0 Wood units)

        Exclusion Criteria:

          -  Patients who meet the criteria for inclusion into WHO Groups II, III, IV or V.

          -  Do not meet the required hemodynamic criteria for entry into the study.

          -  Patients with known history of cancer, malignancy disorders, active infections, and
             chronic or immune-mediated diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Giuditta Benincasa, BiolD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campania &quot;L. Vanvitelli&quot;</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuditta Benincasa, BiolD. MSc</last_name>
    <phone>+39 0815667916</phone>
    <email>giuditta.benincasa@unicampania.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudio Napoli, Professor</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Monaldi Hospital</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuditta Benincasa, BiolD, MSc</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Napoli C, Benincasa G, Loscalzo J. Epigenetic Inheritance Underlying Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):653-664. doi: 10.1161/ATVBAHA.118.312262. Review.</citation>
    <PMID>30727752</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>March 1, 2020</last_update_submitted>
  <last_update_submitted_qc>March 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Giuditta Benincasa</investigator_full_name>
    <investigator_title>Principal Investigator Giuditta Benincasa</investigator_title>
  </responsible_party>
  <keyword>Adaptive immunity</keyword>
  <keyword>DNA methylome</keyword>
  <keyword>RNA-sequencing</keyword>
  <keyword>Network analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Vascular Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

